Cardioprecision Ltd.

CardioPrecision is a MedTech company developing medical technology and products for minimally invasive treatment of structural heart disease. The company principally focused on the innovative transcervical approach for minimally invasive aortic valve surgery and interventions. It allows clinicians to perform minimally invasive procedures through a very small access in the neck. The company’s CoreVista® devices have successfully been used in both Surgical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) procedures. Other cardiovascular applications, such as TMVR, TEVAR, EVAR, LVAD implantation, are envisaged with similar benefits for patients and healthcare providers. Key benefits include much less pain and faster recovery. Secondary benefits may include reduced blood loss, lower rates of transfusion/infection and much shorter hospital stay. CardioPrecision is the World-first for bringing a plug-and-play high-definition screen into the operative field within direct sight and independent control of the operator. At the height of Covid pandemic, the Company successfully launched a suite of CoreVista® devices for use in Endoscopic Vessel Harvesting (EVH) of both radial artery and long saphenous vein, during coronary artery bypass grafting (CABG) surgery. The on-table CoreVista® Monitor is positioned directly in front of the operator, enabling optimised hand-eye coordination for execution of complex motor tasks, while minimising disruption to operating theatre footprint. This innovation could improve learning curve and offers operators more comfortable work posture and personalised workspace. CardioPrecision’s technology could potentially be applied to a wider range of cardiothoracic /cardiovascular procedures. The company is dedicated to making patients’ lives better through the development of innovative, less invasive access solutions for cardiothoracic surgery and cardiovascular interventions.